54 related articles for article (PubMed ID: 8174799)
1. [Viral safety of biologicals].
Barin F
Ann Pharm Fr; 2008 Jun; 66(3):129-39. PubMed ID: 18706341
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of HCV and HIV by microwave: a novel approach for prevention of virus transmission among people who inject drugs.
Siddharta A; Pfaender S; Malassa A; Doerrbecker J; Anggakusuma ; Engelmann M; Nugraha B; Steinmann J; Todt D; Vondran FW; Mateu-Gelabert P; Goffinet C; Steinmann E
Sci Rep; 2016 Nov; 6():36619. PubMed ID: 27857152
[TBL] [Abstract][Full Text] [Related]
3. Endemic impact of human T cell leukemia virus type 1 screening in bone allografts.
Ishidou Y; Matsuyama K; Matsuura E; Setoguchi T; Nagano S; Kakoi H; Hirotsu M; Kawamura I; Yamamoto T; Komiya S
Cell Tissue Bank; 2016 Dec; 17(4):555-560. PubMed ID: 27677902
[TBL] [Abstract][Full Text] [Related]
4. Modern plasma fractionation.
Burnouf T
Transfus Med Rev; 2007 Apr; 21(2):101-17. PubMed ID: 17397761
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the viral safety of antivenoms fractionated from equine plasma.
Burnouf T; Griffiths E; Padilla A; Seddik S; Stephano MA; Gutiérrez JM
Biologicals; 2004 Sep; 32(3):115-28. PubMed ID: 15536042
[TBL] [Abstract][Full Text] [Related]
6. Role of fever in infection: has induced fever any therapeutic potential in HIV infection?
Morton RS; Rashid S
Genitourin Med; 1997 Jun; 73(3):212-5. PubMed ID: 9306904
[TBL] [Abstract][Full Text] [Related]
7. Viral safety of solvent-detergent treated blood products.
Horowitz B; Prince AM; Horowitz MS; Watklevicz C
Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
[TBL] [Abstract][Full Text] [Related]
8. Theoretical and technical concerns in inactivation/elimination of viruses in plasma derivatives.
Hilfenhaus J; Niedrig M; Nowak T
Dev Biol Stand; 1993; 81():117-23. PubMed ID: 8174794
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
10. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
11. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
Nübling CM; Unkelbach U; Chudy M; Seitz R
Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation.
Nowak T; Niedrig M; Bernhardt D; Hilfenhaus J
Dev Biol Stand; 1993; 81():169-76. PubMed ID: 8174799
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
